FDA Approves First Treatment to Reduce Risk of Serious Heart …
Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
News details - Novo Nordisk
Mar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
News Details - Novo Nordisk
Aug 8, 2023 · Wegovy ® is launched in the US, Denmark, Norway and Germany. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
News Details - Novo Nordisk
Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
News details - Novo Nordisk
Nov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with an initial BMI of 27 kg/m 2 or greater and established cardiovascular disease (CVD).
News Details - Novo Nordisk
Mar 8, 2024 · Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application ...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
Apr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
FDA approves Wegovy to reduce heart attack and stroke risk - NBC News
Mar 8, 2024 · The blockbuster weight loss drug Wegovy is now approved to reduce heart disease risk, drugmaker Novo Nordisk said Friday. The Food and Drug Administration has updated the drug's label, saying...
Novo Nordisk cuts profit outlook over disappointing Wegovy sales | CNN ...
Aug 7, 2024 · Novo Nordisk trimmed its full-year profit outlook Wednesday after reporting weaker-than-expected quarterly sales of its popular weight loss drug Wegovy.